Skip to main content
. 2019 Mar 29;7:89. doi: 10.1186/s40425-019-0512-5

Fig. 5.

Fig. 5

Panel a and b shows that overweight/ Class 1 obese males had the longest progression free survival (PFS) among patients treated with monotherapy (a) and combination (b). Panel c and d shows that overweight/Class 1 obese patients with serum creatinine > = 0.9 mg/dL had the longest PFS among patients treated with monotherapy (c) and combination (d)